» Articles » PMID: 37261085

Acquired DNA Damage Repairs Deficiency-driven Immune Evolution and Involved Immune Factors of Local Versus Distant Metastases in Non-small Cell Lung Cancer

Overview
Journal Oncoimmunology
Date 2023 Jun 1
PMID 37261085
Authors
Affiliations
Soon will be listed here.
Abstract

The evolution of immune profile from primary tumors to distant and local metastases in non-small cell lung cancer (NSCLC), as well as the impact of the immune background of primary tumors on metastatic potential, remains unclear. To address this, we performed whole-exome sequencing and immunohistochemistry for 73 paired primary and metastatic tumor samples from 41 NSCLC patients, and analyzed the change of immune profile from primary tumors to metastases and involved genetic factors. We found that distant metastases tended to have a decreased CD8+ T cell level along with an increased chromosomal instability (CIN) compared with primary tumors, which was partially ascribed to acquired DNA damage repair (DDR) deficiency. Distant metastases were characterized by immunosuppression (low CD8+ T cell level) and immune evasion (high PD-L1 level) whereas local metastases (pleura) were immune-competent with high CD8+ T cell, low CD4+ T cell and low PD-L1 level. Primary tumors with high levels of CD4+ T cells were associated with distant metastases rather than local metastases. Analysis of TCGA data and a single-cell RNA-sequencing dataset revealed a decreasing trend of major immune cells, such as CD8+ T cells, and an increasing trend of CD4 T helper cells (Th2 and Th1) in primary tumors with metastases from local to distant sites. Our study indicates that there are differences in the immune evolution between distant and local metastases, and that acquired DDR deficiency contributes to the immunosuppression in distant metastases of NSCLC. Moreover, the immune background of primary tumors may affect their metastatic potential.

Citing Articles

Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.

Meira D, de Castro E Caetano M, Casotti M, Zetum A, Goncalves A, Moreira A Genes (Basel). 2023; 14(10).

PMID: 37895255 PMC: 10606762. DOI: 10.3390/genes14101906.

References
1.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

2.
Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

3.
Li Y, Yang X, Wu Y, Zhao K, Ye Z, Zhu J . B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. 2017; 8(42):71725-71735. PMC: 5641084. DOI: 10.18632/oncotarget.17847. View

4.
Kitamura T, Qian B, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol. 2015; 15(2):73-86. PMC: 4470277. DOI: 10.1038/nri3789. View

5.
Kudo Y, Haymaker C, Reuben A, Duose D, Fujimoto J, Roy-Chowdhuri S . Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol. 2019; 30(9):1521-1530. PMC: 6771224. DOI: 10.1093/annonc/mdz207. View